Loading
A phase 2/3 trial of Alectinib, Atezolizumab, Pemetrexed in non-small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT03178552 by Hoffmann-La Roche, with 1000 participants planned, started 2017-09-22 and due to reach its primary completion in 2027-06-30. Interventions recorded: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Small-cell lung cancer, Cisplatin, Carboplatin.
Shares Roche / Genentech, Pemetrexed, Small-cell lung cancer, Cisplatin.
Shares Pemetrexed, Gemcitabine, Small-cell lung cancer, Cisplatin.
Shares Roche / Genentech, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, Small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, Gemcitabine, Cisplatin, Carboplatin.
Shares Pemetrexed, Gemcitabine, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/